Longeveron is a biotech focused on mesenchymal stromal/stem cells or MSCs. Its big news this year was a report in Cell Stem Cell about a potential benefit for frailty from its product laromestrocel. I’ll talk more about that and my concerns further down. Now Longeveron posted results from another trial of laromestrocel; this one gave […]
The post Weekly reads: Longeveron MSC trial disappoints, CRISPR ancestor VIPR, distinct human brain progenitors, FDA staffing woes appeared first on The Niche.